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summary
Systemic sclerosis (SSc) is a connective tissue disease frequently associated with Raynaud’s Phenomenon 
(RP). Among possible pharmacological treatments, phosphodiesterase 5 inhibitors are considered in cases 
of severe non -responsive RP. We present the case of a male SSc patient wh presented with critical finger 
ischemia and concomitant appearance of myocardial fibrosis after sudden interruption of sildenafil treatment. 
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A sixty-year-old Caucasian man first presented to our center in December 
2010 complaining of a 25 years history of 
Raynaud’s phenomenon (RP), skin thick-
ening of fingers and face, esophageal re-
flux and history of digital ulcerations; he 
was on atorvastatin and allopurinol for 
hypercholesterolemia and hyperuricemia, 
respectively. 
On examination he presented calcinosis 
on the left elbow, sclerodactily with modi-
fied Rodnan skin score of 4/51 and facial 
telangiectasia. The positivity of anti-nu-
clear and anti-centromere antibodies and 
a late scleroderma pattern on nail fold 
videocapillaroscopy (1) supported the 
diagnosis and classification of systemic 
sclerosis (2). Internal organ baseline as-
sessments excluded pulmonary involve-
ment on chest high resolution computed 
tomography and lung function tests, while 
morphologic and functional cardiac ab-
normalities were ruled out on echocar-
diography and cardiac magnetic reso-
nance imaging (MRI). The latter showed 
also absence of delayed contrast medium 
enhancement. Due to previous intolerance 
to calcium-channel blockers and refusal 
to intravenous iloprost, he was started on 
sildenafil 20 mg three times a day for non-
controlled RP. 
The treatment was beneficial until April 
2011, when he stopped all oral medica-
tions for an episode of viral gastroenteri-
tis; two days after he presented to emer-
gency room with a critical ischemia of the 
right index finger: arterial doppler ultra-
sound showed completely absent blood 
flow in the second and third phalanx of 
the finger. 
He was admitted to our unit and started 
on continuous intravenous iloprost and 
low molecular weight heparin, with rapid 
progressive improvement of the ischemic 
problem. A further arterial Doppler ultra-
sound showed a recovery of blood flow 
and repeated cardiac MRI showed delayed 
gadolinium enhancement at the inferior 
septum-ventricular junction (Figure 1). 
This suggested the presence of myocardi-
al fibrosis with non-coronary distribution 
(patchy fibrosis) and without inducible 
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heart ischemia on perfusional miocardial 
single positron emission tomography later 
performed (3). 
The patient was discharged with all pre-
vious medications plus prescription for 
monthly iloprost infusion and daily low 
dose aspirin.
To our knowledge, this is the first report of 
acute peripheral ischemic attack after sud-
den interruption of phosphodiesterase-5 
inhibitors chronic vasodilating treatment 
(4), which led not only to ischemic fin-
ger suffering but also to tissue myocardial 
modifications (5, 6). In our case, cardiac 
MRI was useful in detecting early myo-
cardial involvement. 
MRI was previously suggested as a 
screening tool to analyze non-symptom-
atic scleroderma patients and identify 
subclinical involvement (7-9). According 
to the previously proposed hypothesis of 
myocardial RP (10), we believe that the 
development of myocardial fibrosis could 
have been the effect of a sufferance of epi-
cardial coronaries due to a prolonged va-
sospasm (11). The possibility of these two 
events being caused by a sildenafil with-
draw rebound effect was never reported 
in previous clinical trials and therefore 
remains unproven.
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